.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

FDA updated Safety Communication: Ondansetron (Zofran) 32-mg, single IV dose pulled due to potential for serious cardiac risks

December 5, 2012

The 32-mg, single intravenous dose of the anti-nausea drug Zofran will no longer be marketed because of the potential for serious cardiac risk, according to an updated Safety Communication from FDA.